Related Experiment Video
Updated: Jul 17, 2026

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1
Joo Hyun Kim1, Won Seog Kim, Jung Hun Kang
1Biomedical Research Institute, Samsung Medical Center, 50 Irwon-dong, Kangnam-gu, Seoul 135-710, Republic of Korea.
Abstract:
To investigate the effect of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) on human cancer cells, we sought to identify and analyze potential target genes that were differentially expressed in the presence and absence of LMP1. Our cDNA microarray analysis revealed that expression of early growth response gene-1 (Egr-1) was increased by LMP1 expression in MCF7 and Jurkat cells. An NFkappaB inhibitor (SN50) antagonized LMP1-induced enhancement of Egr-1 expression, indicating that LMP1 induced Egr-1 via NFkappaB. Furthermore, three lines of evidence indicated that Egr-1 was required for LMP1-induced cancer cell survival. First, Egr-1 expression enhanced the survival of doxorubicin-treated MCF7 cells. Second, inhibition of Egr-1 expression by siRNA (siEgr-1) effectively suppressed LMP-1-induced survival of MCF7 cells. Third, Egr-1 knockdown decreased LMP1-induced expression of Bfl-1. Similar relationships among EBV infection, Egr-1 and drug resistance were also observed in tissues of peripheral T-cell lymphoma-unspecified (PTCL-u) patients.
Insights
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) enhances cancer cell survival by upregulating early growth response gene-1 (Egr-1) through the NF-kappaB pathway. This EBV-Egr-1 interaction contributes to drug resistance in human cancers.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Epstein-Barr virus (EBV) is associated with various human cancers.
- Latent membrane protein 1 (LMP1) is a key EBV oncoprotein.
- Understanding LMP1's role in cancer cell survival is crucial for therapeutic development.
Purpose of the Study:
- To identify target genes regulated by EBV LMP1 in human cancer cells.
- To elucidate the mechanism by which LMP1 promotes cancer cell survival.
- To investigate the link between EBV, Egr-1, and drug resistance.
Main Methods:
- cDNA microarray analysis to identify differentially expressed genes.
- Use of NF-kappaB inhibitor (SN50) to study signaling pathways.
- Small interfering RNA (siRNA) to inhibit Egr-1 expression.
- Cell survival assays in doxorubicin-treated MCF7 cells.
- Analysis of patient tissues (PTCL-u).
Main Results:
- LMP1 expression significantly increased early growth response gene-1 (Egr-1) expression in MCF7 and Jurkat cells.
- LMP1-induced Egr-1 expression was mediated via the NF-kappaB pathway.
- Egr-1 was essential for LMP1-mediated cancer cell survival, as shown by Egr-1 overexpression enhancing survival and Egr-1 knockdown suppressing it.
- Egr-1 knockdown reduced LMP1-induced expression of Bfl-1, an anti-apoptotic protein.
- A correlation between EBV infection, Egr-1 levels, and drug resistance was observed in PTCL-u patient tissues.
Conclusions:
- EBV LMP1 promotes cancer cell survival and drug resistance by inducing Egr-1 expression through the NF-kappaB pathway.
- Egr-1 is a critical mediator of LMP1's oncogenic functions.
- Targeting the EBV-LMP1-Egr-1 axis may offer a therapeutic strategy for EBV-associated cancers.
Related Concept Videos
LTR Retrotransposons
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
Non-LTR Retrotransposons
Herpes
Leaky Scanning
Intralumenal Vesicles and Multivesicular Bodies

